Related Experiment Video
Updated: Mar 1, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
Risks of Cefuroxime Prophylaxis for Postcataract Endophthalmitis
Khaled A Al-Abduljabbar1,2, Donald U Stone1,3
1Research Department, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saud Arabia.
Intracameral cefuroxime (ICC) effectively prevents endophthalmitis post-cataract surgery, even in penicillin-allergic patients. Careful preparation is crucial to mitigate risks like ocular toxicity and toxic anterior segment syndrome (TASS).
Area of Science:
- Ophthalmology
- Infectious Disease
- Pharmacology
Background:
- Endophthalmitis is a rare but severe complication following cataract surgery.
- Intracameral cefuroxime (ICC) is utilized for prophylaxis, yet safety concerns persist.
Purpose of the Study:
- To systematically review the literature on intracameral cefuroxime (ICC).
- To specifically evaluate the risks associated with ICC therapy for endophthalmitis prophylaxis.
Main Methods:
- Systematic literature review and synthesis.
- Focus on identifying and analyzing risks of ICC therapy.
Main Results:
- Evidence supports cefuroxime use in penicillin-allergic patients.
- Compounding/dilutional errors may cause ocular toxicity; incidence is unknown.
- No established link between cefuroxime and toxic anterior segment syndrome (TASS); standard measures recommended.
Conclusions:
- Cefuroxime is safe for penicillin-allergic patients.
- Minimizing preparation errors is vital to maximize ICC benefits.
- Clinical practice guidelines should weigh ICC risks and benefits for endophthalmitis prevention.
More Related Videos
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Endocarditis IV: Nursing Management
Cardiac Catheterization I: Pre-Procedure Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...

